<DOC>
	<DOCNO>NCT02566772</DOCNO>
	<brief_summary>The purpose trial investigate safety tolerability TAS3681 find maximum tolerate dose TAS3681 .</brief_summary>
	<brief_title>Study TAS3681 Metastatic Castration Resistant Prostate Cancer</brief_title>
	<detailed_description>This first human , multinational , phase 1 , open-label study TAS3681 patient metastatic castration resistant prostate cancer ( mCRPC ) evaluate safety , tolerability , pharmacokinetics preliminary antitumor activity patient mCRPC standard therapy . Eligible patient either enrol dose escalation phase evaluate safety determine maximum tolerate dose TAS3681 expansion phase additional cohort patient may enrol evaluate safety preliminary efficacy TAS3681 MTD low dose . Approximately 50 evaluable patient enrol Dose Escalation Phase approximately 80 patient enrolled Expansion Phase .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Male &gt; 18 year age 2 . Histological cytological evidence metastatic prostate cancer progression define PCWG3 ; Scher HI 2015 intolerance standard chemotherapy 3 . ECOG performance status &lt; 1 Day1 Cycle 1 4 . Ongoing androgen deprivation serum testosterone &lt; 50 ng/dl 5 . Ability take medication orally 6 . Adequate organ function 7 . Willing comply schedule visit procedure 1 . QTc &gt; 450ms , history Qtc prolongation predisposition QTc prolongation family history sudden cardiac death QT prolongation 2 . History presence heart failure leave ventricular dysfunction ejection fraction &lt; 40 % within previous 6 month ; &gt; 6 month cardiac function within normal limit free cardiacrelated symptom 3 . History presence atrial fibrillation , atrial flutter paroxysmal supraventricular tachycardia ; presence history ventricular arrhythmia include ventricular fibrillation ventricular tachycardia 4 . Presence cardiac pacemaker implantable cardioverterdefibrillator 5 . History presence bradydysrhythmia conduction abnormalities 6 . History presence cardia arrest unexplained syncope 7 . Hypokalemia 8 . History myocardial infarction severe unstable angina 9 . Any medication administer within 4 week prior 1st dose TAS3681 know affect QT interval arrhythmogenic 10 . Received treatment prohibit trial 11 . Serious illness medical condition could affect safety tolerability study treatment 12 . Received prior treatment TAS3681 13 . User herbal product 14 . Any condition reason opinion investigator , interfere ability patient participate trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
</DOC>